Mikan (Amikacin)

Amikacin, the active ingredient in Mikan, is a aminoglycoside antibiotic presented as a strength/form for intramuscular, intravenous use. It treats severe Gram‑negative bacterial infections, sepsis, hospital‑acquired pneumonia and related serious infections in hospitalized patients.

GNH USA supplies Mikan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Amikacin is an aminoglycoside antibiotic used to treat infections caused by Gram‑negative bacteria.

Severe Gram‑negative bacterial infections: provides bactericidal activity to eradicate the pathogen. Sepsis: rapidly reduces bacterial load in systemic infection. Hospital‑acquired pneumonia: targets resistant Gram‑negative organisms in the lungs. Complicated urinary tract infections: eliminates causative bacteria in the urinary system. Intra‑abdominal infections: treats polymicrobial Gram‑negative infections within the abdominal cavity.

Amikacin may cause a range of adverse reactions, from mild to severe, depending on patient factors and duration of therapy.

Common Side Effects: - Ototoxicity: hearing loss or tinnitus. - Nephrotoxicity: elevated serum creatinine or reduced urine output. - Vestibular dysfunction: dizziness or balance disturbances. - Injection site reactions: pain, erythema, or swelling. - Rash or mild skin eruptions. - Nausea or vomiting.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Respiratory failure: difficulty breathing or respiratory depression. - Neuromuscular blockade: muscle weakness, especially in patients with myasthenia gravis. - Severe renal impairment: acute kidney injury requiring dialysis. - Permanent hearing loss: irreversible auditory damage. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating amikacin therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.

Renal function monitoring: check serum creatinine and urine output regularly. Hearing assessment: perform baseline and periodic audiometry. Dose adjustment in renal impairment: modify dose according to glomerular filtration rate. Pregnancy caution: avoid unless benefits outweigh risks (Category D). Avoid in patients with known neuromuscular disorders: risk of blockade. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amikacin can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent nephrotoxic agents (e.g., vancomycin, amphotericin B): increase risk of kidney injury. - Loop diuretics (e.g., furosemide): potentiate nephrotoxicity. - Other aminoglycosides: additive ototoxic and nephrotoxic effects. - Neuromuscular blocking agents (e.g., succinylcholine): enhance muscle weakness. - High-dose penicillins: may reduce antibacterial activity.

Moderate Interactions (Monitor Closely): - NSAIDs: may modestly increase renal risk. - Diuretics (thiazides): require renal function checks. - Ototoxic drugs (e.g., loop diuretics, cisplatin): monitor hearing. - Antacids containing magnesium or aluminum: may affect absorption if oral form used. - Rifampin: may reduce serum concentrations.